This is our heavily anticipated episode on the weight loss drugs that have been receiving a ton of media attention recently, including Ozempic and Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide), and others.

Since these drugs are intimately involved with our bodies' hormone regulation, we had to bring in an hormone expert to break it down for us. Dr. Karl Nadolsky is one of the best in this space, and is both a nationally recognize expert in obesity medicine, and a Navy veteran who worked extensively on these issues with active duty service members at Walter Reed.

Karl is a clinical endocrinologist and chief of the endocrinology, obesity & diabetes department for Holland Hospital in Holland, MI. He is an assistant clinical professor of medicine for Michigan State University College of Human Medicine. He holds board certification in Internal Medicine, Diabetes Endocrinology & Metabolism, and Obesity Medicine.

You may know him from the Docs Who Lift podcast which he co-hosts with his brother Spencer, who is also a doctor specializing in obesity medicine. Both of the brothers are accomplished athletes in addition to their medical credentials, giving them a unique perspective on the appropriate combinations of medical and lifestyle interventions.

You can listen to the Docs Who Lift podcast on Spotify here (or on your preferred listening app).

You can find Karl's article on obesity pharmacotherapy in active duty military populations here.

You can follow Karl on his Instagram for some excellent health and fitness content, and if you want to follow both of the Docs Who Lift, you can follow Spencer on his page as well.